ClinicalTrials.gg
RecruitingNCT07532382Updated Apr 15, 2026

Personalized Stories for Pediatric Kidney Recipients

An observational study in Kidney Transplant, sponsored by Paris Translational Research Center for Organ Transplantation. Recruiting at 1 site in France. Open to participants aged 5 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Paris Translational Research Center for Organ Transplantation · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
5 Years to 12 Years
Sex
All
01

Study summary

Pediatric kidney transplant recipients often face major psychosocial challenges that are difficult to address with existing tools. This study evaluates whether clinically supervised AI can generate personalized, age-adapted therapeutic stories for these children and their families.

Read the detailed description

Pediatric kidney transplant recipients face substantial psychosocial challenges, including anxiety, fear, difficulty understanding complex medical experiences, and challenges returning to school and social life. Therapeutic storytelling may help children process these experiences, but truly personalized stories are difficult to produce manually at scale. Large language models offer the opportunity to generate age-adapted, personalized, and clinically supervised stories. This study aims to develop and evaluate an AI-assisted storytelling workflow for pediatric kidney recipients and their families.

02

Conditions studied

  • Kidney Transplant

Keywords

  • Artificial intelligence
03

In context

Lead sponsor

Paris Translational Research Center for Organ Transplantation is the lead sponsor of 31 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pediatric kidney recipients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 5-12 years inclusive at enrolment.
  • Recipient of a kidney transplant.
  • Clinically stable at enrolment (no active rejection, acute infection, or current hospitalization for a graft-related complication).
  • Fluency in French or English.
  • Written from parent(s)/legal guardian(s); child assent when age-appropriate.

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive impairment precluding engagement with narrative content.
  • Mental state not allowing participation.
  • Family unwilling or unable to commit to the study timeline and interview requirements.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pediatric kidney recipient

    Other: AI-generated story · Other: AI generated story

Interventions

  • OtherAI-generated story

    A story generated by artificial intelligence is created and personalized for pediatric kidney recipient

  • OtherAI generated story

    This is a minimal-risk observational study. Families complete a questionnaire and receive an AI-generated, clinically supervised personalized story. During the pilot phase, there is no direct child-AI interaction. All stories are reviewed by the clinical lead before delivery.

06

What researchers measure

Primary outcomes

  1. Child and family experience of the story after delivery.

    Child and family experience of the story, assessed through qualitative feedback, thematic analysis, and satisfaction ratings collected after story delivery.

    Time frame: One month after story delivery

  2. Child and family experience of the story after delivery.

    Child and family experience of the story, assessed through qualitative feedback, thematic analysis, and satisfaction ratings collected after story delivery.

    Time frame: One month after the story is delivered

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lorenzini G, Arbelaez Ossa L, Milford S, Elger BS, Shaw DM, De Clercq E. The "Magical Theory" of AI in Medicine: Thematic Narrative Analysis. JMIR AI. 2024 Aug 19;3:e49795. doi: 10.2196/49795. PubMed 39158953 ↗

Individual participant data

Plan to share: No — These will be data related to pediatric kidney recipients.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 15, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07532382
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Responsible party
Marc Raynaud (Scientific leader, Paris Translational Research Center for Organ Transplantation) — Principal investigator
First posted
Apr 15, 2026
Start date
Mar 1, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Apr 15, 2026

Study contacts

Marc Raynaud, PhD
Contact
mrayna06@gmail.com
+33613493009
Marc Raynaud, PhD
principal investigator · Paris Institute for Transplantation and Organ Regeneration
Evgenia Preka, MD, PhD
principal investigator · Paris Institute for Transplantation and Organ Regeneration

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion